北京大学学报(医学版) ›› 2017, Vol. 49 ›› Issue (5): 749-752. doi: 10.3969/j.issn.1671-167X.2017.05.001
• 述评 • 下一篇
杜军保, 陈咏冰
中图分类号:
| [1] 江载芳, 申昆玲, 沈颖. 诸福棠实用儿科学[M] . 8版. 北京: 人民卫生出版社, 2015: 778-788. [2] Burns JC, Glode MP. Kawasaki syndrome [J]. Lancet, 2004, 364(9433): 533-544. [3] Patel RM, Shulman ST. Kawasaki disease: A comprehensive review of treatment options [J]. J Clin Pharm Ther, 2015, 40(6): 620-625. [4] McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of kawasaki disease: a scientific statement for health professionals from the American Heart Association [J]. Circulation, 2017, 135(17): e927-e999. [5] Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: A statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association [J]. Circulation, 2004, 110(17): 2747-2771. [6] Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome [J]. N Engl J Med, 1991, 324(23): 1633-1639. [7] Burns JC, Capparelli EV, Brown JA, et al. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease [J]. Pediatr Infect Dis J, 1998, 17(12): 1144-1148. [8] Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease [J]. Circulation, 2006, 113(22): 2606-2612. [9] Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease [J]. J Pediatr, 2006, 149(2): 237-240. [10] Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment [J]. Eur J Pediatr, 2007, 166(2): 131-137. [11] Sleeper LA, Minich LL, McCrindle BM, et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance [J]. J Pediatr, 2011, 158(5): 831-835. [12] Park HM, Lee DW, Hyun MC, et al. Predictors of nonresponse to intravenous immunoglobulin therapy in Kawasaki disease [J]. Korean J Pediatr, 2013, 56(2): 75-79. [13] Tremoulet AH, Best BM, Song S, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease [J]. J Pediatr, 2008, 153(1): 117-121. [14] Yoshimura K, Kimata T, Mine K, et al. N-terminal pro-brain natriuretic peptide and risk of coronary artery lesions and resistance to intravenous immunoglobulin in Kawasaki disease [J]. J Pediatr, 2013, 162(6): 1205-1209. [15] Sato S, Kawashima H, Kashiwagi Y, et al. Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients [J]. Int J Rheum Dis, 2013, 16(2): 168-172. [16] 杜忠东, 张永兰, 赵地, 等. 静脉丙种球蛋白无反应性川崎病的治疗及危险因素分析[J]. 中国实用儿科杂志, 2006, 21(10): 738-741. [17] Do YS, Kim KW, Chun JK, et al. Predicting factors for refractory Kawasaki disease [J]. Korean Circ J, 2010, 40(5): 239-242. [18] Kuo HC, Liang CD, Wang CL, et al. Serum albumin level predicts initial intravenous immunoglobulin treatment failure in Kawasaki disease [J]. Acta Paediatr, 2010, 99(10): 1578-1583. [19] Kim HK, Oh J, Hong YM, et al. Parameters to guide retreatment after initial intravenous immunoglobulin therapy in Kawasaki disease [J]. Korean Circ J, 2011, 41(7): 379-384. [20] Uehara R, Belay ED, Maddox RA, et al. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan [J]. Pediatr Infect Dis J, 2008, 27(2): 155-160. [21] Lee SM, Lee JB, Go YB, et al. Prediction of resistance to standard intravenous immunoglobulin therapy in Kawasaki disease [J]. Korean Circ J, 2014, 44(6): 415-422. [22] Nomura Y, Masuda K, Yoshinaga M, et al. Patients diagnosed with Kawasaki disease before the fifth day of illness have a higher risk of coronary artery aneurysm [J]. Pediatr Int, 2002, 44(4): 353-357. [23] Fukunishi M, Kikkawa M, Hamana K, et al. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset [J]. J Pediatr, 2000, 137(2): 172-176. [24] Muta H, Ishii M, Egami K, et al. Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan [J]. J Pediatr, 2004, 144(4): 496-499. [25] Muta H, Ishii M, Furui J, et al. Risk factors associated with the need for additional intravenous gamma-globulin therapy for Kawasaki disease [J]. Acta Pediatr, 2006, 95(2): 189-193. [26] Fu PP, Du ZD, Pan YS. Novel predictors of intravenous immunoglobulin resistance in chinese children with Kawasaki disease [J]. Pediatr Infect Dis J, 2013, 32(8): E319-E323. [27] Tang YJ, Yan WH, Sun L, et al. Prediction of intravenous immunoglobulin resistance in Kawasaki disease in an east China population [J]. Clin Rheumatol, 2016, 35(11): 2771-2776. [28] Durongpisitkul K, Soongswang J, Laohaprasitiporn D, et al. Immunoglobulin failure and retreatment in Kawasaki disease [J]. Pediatr Cardiol, 2003, 24(2): 145-148. [29] Azab B, Zaher M, Weiserbs KF, et al. Usefulness of neutrophil to lymphocyte ratio in predicting short- and long-term mortality after non-ST-elevation myocardial infarction [J]. Am J Cardiol, 2010, 106(4): 470-476. [30] Ha KS, Lee J, Jang GY, et al. Value of neutrophil-lymphocyte ratio in predicting outcomes in Kawasaki disease [J]. Am J Cardiol, 2015, 116(2): 301-306. [31] Kawamura Y, Takeshita S, Kanai T, et al. The combined usefulness of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in predicting intravenous immunoglobulin resistance with Kawasaki disease [J]. J Pediatr, 2016, 178: 281-284.e1. [32] Cho HJ, Bak SY, Kim SY, et al. A high neutrophil to lymphocyte ratio is associated with refractory Kawasaki disease [J]. Pediatr Int, 2017, 59(6): 669-674. [33] Cho KH, Kang SJ. Clinically useful predictors of resistance to intravenous immunoglobulin and prognosis of coronary artery lesions in patients with incomplete Kawasaki disease [J]. Korean Circ J, 2014, 44(5): 328-335. [34] Nakamura Y, Yashiro M, Uehara R, et al. Use of laboratory data to identify risk factors of giant coronary aneurysms due to Kawasaki disease [J]. Pediatr Int, 2004, 46(1): 33-38. [35] Aoyagi R, Hamada H, Sato Y, et al. Study protocol for a phase Ⅲ multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin a in patients with severe Kawasaki disease (KAICA trial) [J]. BMJ Open, 2015, 5(12): e009562. [36] 胡坚. 川崎病急性期治疗进展[J]. 中国实用儿科杂志, 2015, 30(1): 1-4. |
| [1] | 袁临天,马利沙,刘润园,齐伟,张栌丹,王贵燕,王宇光. 计算机模拟亚甲基蓝与牙龈卟啉单胞菌部分蛋白的分子对接[J]. 北京大学学报（医学版）, 2022, 54(1): 23-30. |
| [2] | 唐迅,张杜丹,刘晓非,刘秋萍,曹洋,李娜,黄少平,窦会东,高培,胡永华. China-PAR脑卒中模型在北方农村人群中预测脑卒中发病风险的应用[J]. 北京大学学报（医学版）, 2020, 52(3): 444-450. |
| [3] | 朱学华,杨明钰,夏海缀,何为,张智荧,刘余庆,肖春雷,马潞林,卢剑. 机器学习模型在预测肾结石输尿管软镜碎石术后早期结石清除率中的应用[J]. 北京大学学报（医学版）, 2019, 51(4): 653-659. |
| [4] | 唐雯,高峻逸,马辛宇,张超贺,马连韬,王亚沙. 循环神经网络模型在腹膜透析临床预后预测中的初步应用[J]. 北京大学学报（医学版）, 2019, 51(3): 602-608. |
| [5] | 蔺轲，谢俊卿，胡永华，孔桂兰. 支持向量机在ICU急性肾损伤患者住院死亡风险预测中的应用[J]. 北京大学学报(医学版), 2018, 50(2): 239-244. |
| [6] | 张茗茗，郑迎东，梁宇红. 牙髓根尖周病根管治疗疗效预测模型的建立[J]. 北京大学学报(医学版), 2018, 50(1): 123-130. |
| [7] | 唐迅，张杜丹，何柳，曹洋，王晋伟，李娜，黄少平，窦会东，高培，胡永华. China-PAR模型在北方农村人群中预测动脉粥样硬化性心血管疾病发病风险的应用[J]. 北京大学学报(医学版), 2017, 49(3): 439-445. |
| [8] | 李运, 陈克终, 隋锡朝, 卜梁, 周足力, 杨帆, 刘彦国, 赵辉, 李剑锋, 刘军, 姜冠潮, 王俊. 孤立性肺结节良恶性判断数学预测模型的建立[J]. 北京大学学报（医学版）, 2011, 43(3): 450-454. |
| [9] | 任正洪, 安琳, 张伶俐. 应用残差自回归模型预测2020年我国妇幼卫生健康指标[J]. 北京大学学报（医学版）, 2010, 42(2): 221-224. |
| [10] | 李岳玲, 钱秋瑾, 王玉凤. 儿童注意缺陷多动障碍成人期预后及其预测因素[J]. 北京大学学报（医学版）, 2007, 39(3): 337-340. |
| [11] | 芮伟, 张其鹏, 石磊, 卢铭, 景霞, 国强华, 尚彤. SARS冠状病毒可能编码蛋白质的三级结构预测[J]. 北京大学学报（医学版）, 2003, 35(z1): 135-136. |
| [12] | 林国基, 贾珣, 欧阳颀. 用小世界网络模型研究SARS病毒的传播[J]. 北京大学学报（医学版）, 2003, 35(z1): 66-69. |
| [13] | 黄宏思, 郝洁, 谢蜀生. 抗Ia单克隆抗体促进异基因皮肤移植耐受[J]. 北京大学学报（医学版）, 2000, 32(4): 340-342. |
|
